New York Clinical Trials for Pleural Mesothelioma
1. Memorial Sloan Kettering, New York, NY
Name of Study:
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Study type:
Interventional
Purpose:
To determine if giving chemotherapy in conjunction with pleural IMRT is safe. If it is safe can it keep the tumor under control for a longer period of time than chemotherapy followed by IMRT
ClinicalTrials.gov Identifier:
NCT02639767
Status:
Active December 2015 – December 2018; 12 participants
Location:
Memorial Sloan Kettering at Basking Ridge New Jersey Memorial Sloan Kettering Cancer Center New York
Contact:
Marjorie Zauderer, MD
646-888-4656
2. Memorial Sloan Kettering, New York, NY
Name of Study:
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
Study type:
Interventional
Purpose:
Patients will undergo pleurectomy/decortication followed by chemotherapy and then pleural IMRT to the pleura
ClinicalTrials.gov:
NCT00715611
Status:
Currently recruiting July 2008-July 2017; Estimated participants 81
Location:
Memorial Sloan Kettering New Jersey and New York
Contact:
Andreas Rimner, MD
212-639-6025
Chapter 1 – Valerie Rusch MD
212-639-5873
3. Memorial Sloan Kettering Cancer Center, New York, NY
Name of Study:
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Study type:
Interventional
Purpose:
The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib in combination with steroids, has on the lungs. Furthermore, such treatments side effects will be studied with quality of life. In addition, the investigators would like to determine whether they can find markers in the blood which predict worsening lung injury.
ClinicalTrials.gov:
NCT02496585
Status:
Currently recruiting, Enrolling Start date July 2015- Completion date- July 2019 Estimated Enrollment 68
Location:
Memorial Sloan Kettering Cancer Center New York and New Jersey
Contact:
Andreas Rimner, MD
212-639-6025
4. Memorial Sloan Kettering Cancer Center, New York, NY
Name of Study:
Clinical and Histopathologic Characteristics of BAP1 Mutation
Study type:
Observational
Purpose:
The goal of this protocol is to determine the prevalence of somatic and germline mutations in BAP1 (BRCA associated protein-1) among patients with mesothelioma, choroidal nevus, primary uveal melanoma (UM), or metastatic UM seen at our institution
ClinicalTrials.gov:
NCT01773655
Status:
Currently recruiting January 2013- Completion date January 2017; Estimated enrollment 460
Location:
Memorial Sloan Kettering Cancer Center New York, New York
Contact:
Marjorie Zauderer MD
646-888-4656
David Abramson MD
212-639-7232
5. Memorial Sloan Kettering Cancer Institute, New York, NY
Name of Study:
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Study type:
Interventional
Purpose:
The purpose of this study is to test the safety of the GL-ONC1 vaccinia virus at different dose levels. The investigators want to find out what effects good and/or bad, it has on the patientand the malignant pleural effusion. A malignant pleural effusion is a build up of the fluid in the chest cavity caused by the cancer
ClinicalTrials.gov:
NCT01766739
Status:
Currently recruiting – January 2013- completion date January 2017; Estimated enrollment 34
Location:
Memorial Sloan Kettering Cancer Institute New York, New York
Contact:
Valerie Rusch MD
212-639-5873
Prasad Adusumilli MD
212-639-8093
6. Memorial Sloan Kettering Cancer Center, New York, NY
Name of Study:
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Study type:
Interventional
Purpose:
The purpose of this Phase l study is to test the safety of different doses of specially prepared immune cells (called “Tcells”) collected from blood. The Investigators want to find a safe dose of these modified T cells for patients who have malignant pleural disease. They want to find out what effects these T cells have on the patient and the cancer (MPD)
ClinicalTrials.gov:
NCT02414269
Status:
Currently recruiting May 2015- finish date April 2018; Estimated enrollment 24
Location:
Memorial Sloan Kettering Cancer Center New York, New York
Contact:
Prasad Adusumilli MD
212-639-8093
7. Memorial Sloan Kettering Cancer Center, New York, NY
Name of Study:
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC)
Study type:
Interventional
Purpose:
This is a study of ADl-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADl-PEG 20, the malignant pleural mesothelioma cells will starve and die.
ClinicalTrials.gov:
NCT02709512
Status:
Currently Recruiting-Oct. 2016 – June 2018, Estimated enrollment 386
Location:
In the US Memorial Sloan Kettering Cancer Center New York, New York, Sponsor is The Polaris Group
Contact:
Huong Lee
plee@polarispharma.com
Mesothelioma Clinical Trial Information
Learn More About Mesothelioma
Did You Know?
Get Help from Experienced Mesothelioma Nurses
Learn more about these experienced mesothelioma nurses by watching the video below. Click here to contact a mesothelioma nurse now.
Learn More About MesoLawyersCare
Watch the video below to learn why MesoLawyersCare is the best choice to represent you and your family after a mesothelioma diagnosis.
Contact MesoLawyersCare Now
If you or a loved one has been diagnosed with mesothelioma, please contact us to see if we can help you get the compensation you deserve from the billions of dollars in asbestos trust funds available now for qualified asbestos victims. With just one call, you can put all our experience and success to work for you.
We have represented thousands of victims of mesothelioma and their families in virtually every State in the country and in decades of work have recovered billions of dollars in financial compensation for our clients.
Call us now at 1-888-568-1177, fill out the form on this page or chat with a live person. The consultation is free and it costs nothing upfront to hire the lawyers behind MesoLawyersCare. We only get paid if you collect a settlement or verdict and you will never receive a bill from us.
Receive a
FREE No Obligation
Legal Consultation Today
Important Notice: We are unable to help if:
- Diagnosis or passing was more than three years ago
- An attorney has already been retained in this matter
“You have all been so wonderful to us, so professional, and always looking out for our best interests in every way. I know it’s a job you do. However, not once did anyone ever make us feel like we did not matter.”